Hims & Hers Acquires Eucalyptus for $1.15 Billion, Launches AI Tests
Hims & Hers agreed to acquire Australian digital health company Eucalyptus for $1.15 billion in cash, marking its largest deal to date and expanding its global footprint. The firm also unveiled AI-driven preventive care services—menopause, low testosterone and multi-cancer tests—to deepen its personalized digital health platform.
1. Acquisition of Eucalyptus
Hims & Hers Health agreed to purchase Australian digital health company Eucalyptus for $1.15 billion in cash. The transaction represents Hims & Hers’ largest deal to date and provides access to Eucalyptus’s platform in Australia and New Zealand, strengthening the company’s international reach.
2. Expansion of AI-Driven Preventive Care
Alongside the acquisition, Hims & Hers announced the rollout of AI-driven preventive care services, including menopause support, low testosterone monitoring and multi-cancer screening tests. These offerings aim to enhance the personalized digital health platform by integrating advanced diagnostics and tailored care pathways.
3. Market Reaction and Outlook
Shares of Hims & Hers climbed 1.2% following the announcements, reflecting investor confidence in the combined growth prospects. Management forecasts that the deal and new AI services will accelerate subscriber growth and drive revenue diversification over the next 12 to 18 months.